Myomo (MYO) Cash from Operations Growth (1y) (2017 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -7.20% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 132.40% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | 6.69% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | -35.67% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | -84.38% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 122.43% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 185.96% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | 16.00% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 28.60% |
| 10 | Myomo | 44.63 Mn | 26.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -22.40% |
| Jun 30, 2025 | -362.72% |
| Mar 31, 2025 | 17.52% |
| Dec 31, 2024 | 242.87% |
| Sep 30, 2024 | 12.87% |
| Jun 30, 2024 | -571.02% |
| Mar 31, 2024 | -78.65% |
| Dec 31, 2023 | 4.40% |
| Sep 30, 2023 | 38.73% |
| Jun 30, 2023 | 89.22% |
| Mar 31, 2023 | 21.78% |
| Dec 31, 2022 | -34.76% |
| Sep 30, 2022 | -26.12% |
| Jun 30, 2022 | 21.83% |
| Mar 31, 2022 | -9.93% |
| Dec 31, 2021 | -61.40% |
| Sep 30, 2021 | -23.29% |
| Jun 30, 2021 | 7.32% |
| Mar 31, 2021 | 13.59% |
| Dec 31, 2020 | 57.15% |
| Sep 30, 2020 | 21.41% |
| Jun 30, 2020 | -59.78% |
| Mar 31, 2020 | 21.63% |
| Dec 31, 2019 | -5.22% |
| Sep 30, 2019 | 7.76% |
| Jun 30, 2019 | 2.45% |
| Mar 31, 2019 | -37.72% |
| Dec 31, 2018 | -62.96% |
| Sep 30, 2018 | -33.19% |
| Jun 30, 2018 | -47.93% |
| Mar 31, 2018 | -94.99% |
| Dec 31, 2017 | -70.62% |
| Sep 30, 2017 | -41.84% |